Versant Capital Management
DFTX icon

Versant Capital Management’s Definium Therapeutics DFTX Stock Holding History

Versant Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.42K Hold
90
– – ﹤0.01% 2520
2026
Q2 		$4.23K Buy
+90
New +$2.22K ﹤0.01% 2455
2025
Q2 		– Sell
-1,137
Closed -$6.65K – 2696
2025
Q1 		$6.65K Buy
+1,137
New +$8.14K ﹤0.01% 1915

Other funds holding DFTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Versant Capital Management's DFTX Position: Q3 2026 in Review

Versant Capital Management held its Definium Therapeutics (DFTX) position steady in Q3 2026 at 90 shares worth $3.42K. The position accounts for ﹤0.01% of the portfolio, ranked #2520.

Versant Capital Management first reported a position in DFTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $6.65K in Q1 2025. 125 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Versant Capital Management held 90 shares of Definium Therapeutics worth $3.42K as of Q3 2026.
  • Versant Capital Management left its Definium Therapeutics share count unchanged in Q3 2026.
  • Definium Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2520 holding.
  • Versant Capital Management first reported a position in Definium Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Versant Capital Management's Definium Therapeutics position peaked at $6.65K in Q1 2025.
  • 125 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.